UPDATE: argenx SE (ARGX) PT Lowered to $319 at Credit Suisse

March 3, 2022 1:24 PM EST
Get Alerts ARGX Hot Sheet
Price: $373.83 -0.78%

Rating Summary:
    16 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 0
Join SI Premium – FREE
(Updated - March 3, 2022 1:24 PM EST)

Credit Suisse analyst Tiago Fauth lowered the price target on argenx SE (NASDAQ: ARGX) to $319.00 (from $346.00) while maintaining a Neutral rating.

The analyst comments "ARGX announced that Vyvgart launched commercially in early January, with the salesforce interacting with over 60% of the top 1,000 priority neurologists as of the end of February. As of this week, payer coverage includes 25% of U.S. commercial lives, and mgmt expects to have broad coverage (>50%) in place by the Q2’22. The company is encouraged by the gradual and consistent initial demand eight weeks into launch, highlighting that feedback from physicians have been consistent with expectations. While mgmt will not provide guidance this year, it notes it is comfortable with 2022 consensus sales estimates of $97M. Outside the U.S., Vyvgart is on track to launch in Japan in Q2’22, receive an EMA decision in H2’22, and file for approval in Israel and China in mid-2022."

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Credit Suisse